Unreasonably harsh market reaction to a decent Q3 update
05/11/26 -"The Q3 qualitative update did not materially change the full-year outlook, as Branded’s strong momentum made up for the relative weakness in Injectables and in-line performance of Hikma Rx. While a ..."
Pages
53
Language
English
Published on
05/11/26
You may also be interested by these reports :
05/11/26
The Q3 qualitative update did not materially change the full-year outlook, as Branded’s strong momentum made up for the relative weakness in ...
04/11/26
The weight-loss Wegovy pill drove the Q3 beat, while most key drugs suffered from pricing and competitive pressures. With the previous outlook being ...
04/11/26
“If a man knows not to which port he sails, no wind is favourable.” The Roman philosopher Seneca’s line may strike a chord with GSK’s (BUY; UK) ...
04/11/26
BioNTech’s Q3 operational performance exceeded expectations, driven by higher outlicensing sales from Bristol-Myers Squibb. 2026 sales guidance was ...